论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
肿瘤和T细胞中 SMAD4 突变和异常表达的后果
Received 17 December 2020
Accepted for publication 18 March 2021
Published 13 April 2021 Volume 2021:14 Pages 2531—2540
DOI https://doi.org/10.2147/OTT.S297855
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Leo Jen-Liang Su
Abstract: SMAD4 is a typical tumor suppressor in the TGF-β signaling pathway. In human cancers, SMAD4 is frequently mutated and inactivated. In recent years, the consequences of mutations and inactivation of SMAD4 are gradually becoming clearer. Most of the mutations have negative consequences and reduce the chances of survival of their carriers. Loss of SMAD4 functions due to mutations or abnormal expression can suppress the inhibition of tumor growth and support the tumor progression. Functions of SMAD4 and its variants in T cells are being studied extensively, to better understand the SMAD4 functions in T cells. In this review, we mainly discuss the recently reported consequences of mutations and abnormal expression of SMAD4 in tumors, and the effects of loss, deficiency or mutation of SMAD4 and its T cells, to show the use of SMAD4 mutations in cancer diagnosis and therapeutic strategies.
Keywords: SMAD4, mutation, abnormal expression, T cell, TGF-β